Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway

Publication date: September 2021Source: Biomedicine & Pharmacotherapy, Volume 141Author(s): Rong Li, Wenqiang Zhu, Piaopiao Huang, Yang Yang, Fei Luo, Wen Dai, Li Shen, Wenjing Pei, Xiansheng Huang
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research